12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Company News  |  Deals

BioCryst, Presidio deal

BioCryst will acquire Presidio in a stock deal. The combined company will launch with a new name to focus on HCV and hereditary angioedema (HAE). BioCryst will issue 24.5 million shares to Presidio shareholders, which values Presidio at $100.7 million based on BioCryst's Oct. 17 close of $4.11. The deal, slated to close in 1Q13, is contingent on the completion of a $60 million equity financing, of which certain Presidio shareholders have committed $25 million. The...

Read the full 357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >